ESR1 and breast carcinoma: Subsequently, Seargent et al. [23] showed that ahigher affinity, selective PPARγ antagonist, GW9662, had direct antiproliferativeeffects on three breast cancer cell lines of differing phenotypes (ER+, ER−,and p53-null).